Gujarat Kidney IPO Details
The key details of Gujarat Kidney & Super Speciality’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹250.80 Cr |
| Price Range | ₹108 - ₹114 |
| Retail Quota | 10% |
| QIB Quota | 75% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 128 |
| Investment (cut-off price) | ₹14,592 |
| Pre IPO Promotor Holding | 99.10% |
| Post IPO Promotor Holding | 71.45% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Gujarat Kidney IPO Timelines
The IPO process for Gujarat Kidney & Super Speciality includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
22/12/2025
Start Date24/12/2025
End Date29/12/2025
Refund Initiation29/12/2025
Credit of Shares to Demat Ac30/12/2025
Listing DateGujarat Kidney IPO Lot Size
The Gujarat Kidney & Super Speciality IPO has a fixed lot size of 128 shares, at an upper price band of ₹114 per share. For retail investors, the minimum application is 128 shares (1 lot) amounting to ₹14,592, while the maximum is 1,664 shares (13 lots) worth ₹1,89,696. For Small HNI (S-HNI) investors, the minimum application is 1,792 shares (14 lots) worth ₹2,04,288, while the maximum is 8,704 shares (68 lots) amounting to ₹9,92,256. Big HNI (B-HNI) investors need to apply for at least 8,832 shares (69 lots), totaling ₹10,06,848.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 128 | ₹14,592 |
| Retail Maximum | 13 | 1664 | ₹1,89,696 |
| S-HNI Minimum | 14 | 1792 | ₹2,04,288 |
| S-HNI Maximum | 68 | 8704 | ₹9,92,256 |
| B-HNI Minimum | 69 | 8832 | ₹10,06,848 |
Gujarat Kidney IPO Subscription Status
The subscription status for Gujarat Kidney & Super Speciality IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.06x | 5.73x | 19.04x | -- | 5.21x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Gujarat Kidney IPO Company Financials
Gujarat Kidney & Super Speciality reports robust performance in FY2026 June with Total Income of ₹15.27 crores, managing expenses at ₹7.78 crores, and achieving a strong PAT (Profit After Tax) of ₹5.40 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹0.00 | ₹0.01 | -₹0.01 |
| FY 2024 | ₹5.48 | ₹3.21 | ₹1.71 |
| FY 2025 | ₹40.40 | ₹27.63 | ₹9.50 |
| FY 2026 (3 M) | ₹15.27 | ₹7.78 | ₹5.40 |
About Company
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited is a Gujarat-based healthcare provider offering multispeciality services, including secondary and tertiary care, across multiple locations in the state. The company operates seven multispeciality hospitals and four pharmacies, with a total bed capacity of 490 beds, an approved capacity of 455 beds, and an operational capacity of 340 beds.
The hospitals under the company include Gujarat Kidney and Superspeciality Hospital in Vadodara, Gujarat Multispeciality Hospital in Godhra, Raj Palmland Hospital Private Limited in Bharuch, M/s. Surya Hospital and ICU in Borsad, Gujarat Surgical Hospital in Vadodara, and Ashwini Medical Centre in Anand, along with Ashwini Medical Store in Anand. Its service offerings span general and surgical secondary care as well as tertiary super speciality procedures, with Gujarat Superspeciality Hospital providing treatment across internal medicine, general and minimally invasive surgery, orthopaedics and trauma, joint replacement, obstetrics and gynaecology, respiratory care, cardiology, diabetology, and anaesthesiology. As of June 30, 2025, the company employed 89 doctors, 332 nurses, and 338 other staff members.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2019 | Healthcare | Dr. Pragnesh Bharpoda |
Know Before Investing
Gujarat Kidney IPO Strengths
- Gujarat Kidney & Super Speciality operates seven multispeciality hospitals and four pharmacies with around 490 beds across Vadodara, Bharuch and Anand, giving it a strong regional footprint in central Gujarat.
- The company started with kidney care and has expanded into cardiology, neurology, oncology, orthopaedics and critical care, positioning itself as an integrated super speciality provider.
- The business model emphasises leasing and acquisitions of existing hospitals rather than building Greenfield assets, allowing faster capacity addition with relatively lower upfront capex.
- Rising lifestyle diseases (kidney, cardiac, diabetes), lower penetration of quality tertiary care in tier‑2 cities, and increasing insurance coverage support long-term demand for super speciality hospital services in its catchment area.
- Identified use of proceeds for acquisitions and new hospital capex provides a clear near-term expansion roadmap rather than vague growth plans.
Gujarat Kidney IPO Risks
- Analysts note that margins have “boosted” sharply from FY24 onwards, which raises eyebrows about whether current high profitability is sustainable in a competitive and fragmented hospital industry.
- All existing and planned facilities are within Gujarat, which concentrates regulatory, competitive, and economic risks in a single state.
- Successful integration of Parekhs Hospital and further stake in Harmony Medicare, as well as on-time and on-budget completion of the new Vadodara hospital, are critical; delays or integration issues could dilute returns.
- Hospital performance hinges on attracting and retaining specialists; loss of senior consultants or inability to hire for new facilities could impact patient inflows and service quality.
- The healthcare sector faces ongoing scrutiny regarding pricing, package rates, clinical protocols and regulatory compliance; any adverse policy changes can cap margins or increase compliance costs.
Swot Analysis for Gujarat Kidney IPO
Strengths
Cluster Hospital Network, Experienced Medical Workforce, Track Record of Growth
Weaknesses
Geographic Concentration, High Operating Costs, Regulatory & Compliance Burden
Opportunities
Rising Renal Disease Burden, Planned Footprint Expansion, Health Insurance & Schemes
Threats
Dependence on Specialists, Sector Fragmentation, Clinical & Legal Risks
Company Details
Gujarat Kidney & Super Speciality Ltd.
Plot No. 1, City Sarve No. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara, Gujarat, 390020
Phone: +91 265 298 4800
Email: info@gujaratsuperspecialityhospital.com
Website: http://www.gujaratsuperspecialityhospital.com/
IPO Registar Details
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: gujaratkidney.ipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
FAQs
The key objectives of Gujarat Kidney IPO are:
- Proposed acquisition of Parekhs Hospital at Ahmedabad.
- Part-payment of purchase consideration for the already acquired “Ashwini Medical Centre”.
- Funding of capital expenditure requirements of the Company towards setting up of a new hospital in Vadodara.
- Buying robotics equipment for hospital Gujarat Kidney & Super Speciality hospital in Vadodara location.
- Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the Company
- Funding inorganic growth through unidentified acquisitions and General Corporate Purposes.
- Acquisition of additional shareholding in the subsidiary namely “Harmony Medicare Private Limited” at Bharuch
Nirbhay Capital Services Pvt. Ltd. is the book-running lead managers for the Gujarat Kidney IPO.
Gujarat Kidney IPO shows promising growth potential driven by rising renal disease prevalence and insurance coverage. With seven hospitals and 490 bed capacity including 340 operational beds across central Gujarat, its focused nephrology and dialysis model in under served cities supports higher utilisation, better pricing power, and scalable specialty led expansion.
The issue price for the Gujarat Kidney IPO is set between ₹108 to ₹114 per share.
To invest in one lot of Gujarat Kidney IPO, you need ₹13,824 at the lower price band (₹108 per share) or ₹14,592 at the upper price band (₹114 per share) for a lot size of 128 shares.
Gujarat Kidney IPO shares are scheduled to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on December 30, 2025.
Refund/unblocking of funds for Gujarat Kidney IPO will begin on December 29, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Gujarat Kidney IPO shares on listing day (December 30, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.